ROCKLAND, Mass.--(BUSINESS WIRE)--EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company’s multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology’s 64th Annual Meeting, taking place from April 21 to 28, in New Orleans, Louisiana. The data presented will focus on Rebif® (interferon beta-1a), an established therapy for relapsing forms of MS, and ONO-4641 (S1P receptor agonist), an investigational oral drug in Phase II for the treatment of relapsing-remitting MS, for which Merck KGaA signed a collaboration agreement with Ono Pharmaceuticals in October 2011.
